--- title: "Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments" description: "SciSparc Ltd. has enrolled the first patient in its clinical trial for a CBD-based drug to treat children with autism spectrum disorder. The company plans to enroll 60 participants aged 5 to 18 for a " type: "news" locale: "en" url: "https://longbridge.com/en/news/109566212.md" published_at: "2024-03-08T15:55:52.000Z" --- # Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments > SciSparc Ltd. has enrolled the first patient in its clinical trial for a CBD-based drug to treat children with autism spectrum disorder. The company plans to enroll 60 participants aged 5 to 18 for a 20-week trial, comparing the therapy with standard CBD treatment. SciSparc aims to bring the drug to market in Israel initially, with global distribution pending regulatory approvals. Additionally, the company achieved patent approvals in Canada and validation for their core technology patent in 15 European countries. **SciSparc Ltd.** (NASDAQ:SPRC) announced on Friday that it has **enrolled the first patient** in the company's **clinical trial** assessing the efficacy and safety of its **cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder.** **SCI-210** is a combination of **CBD and CannAmide** – the company's Palmitoylethanolamide – which is designed to alleviate ASD symptoms. ### Why It Matters "The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD," said **Oz Adler**, the company's CEO. "We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms.” The Israel-based SciSparc said it will enroll 60 participants between the ages of 5 and 18, for 20 weeks. The goal of the trial, which is designed in consultation with the National Autism Research Center, is to examine how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD. The company signed an agreement with Israel’s manufacturer and distributor of cannabis-based products, **Tikun Olam Cannbit Pharmaceuticals Ltd.** (OTC:TKUNF), to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year. *See also: Cannabis & Children Autism: New Study Claims CBDA Can Help With Behavioral Issues In Kids With ASD* ### What's Next SciSparc intends to sell SCI-210 in Israel initially with an international drug roll-out subject to obtaining the requisite regulatory approvals**.** In the meantime, it was a busy week for the Tel Aviv-based company. ### SpiSparc's Recent Milestones On Wednesday, SpiSparc said in a press release that it had received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment. The patent has been granted by the government agency Canadian Intellectual Property Office. The company also announced that the process of granting and validating its core technology patent is now completed in 15 European countries. This patent covers combinations of cannabinoids and n-acylethanolamines and aligns with the company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. *Now read: Cannabis Can Be A Game-Changer For Improving The Lives Of Autistic Adults* ### SPRC Price Action SciSparc's **shares traded 3.8889% lower at $3.46 per share** at the time of writing on Friday morning. *The **Benzinga Cannabis Capital Conference** is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at **The Diplomat Beach Resort** will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.* Get your tickets now on bzcannabis.com – Prices will increase very soon! ### Related Stocks - [SPRC.US - SciSparc](https://longbridge.com/en/quote/SPRC.US.md) - [CBDBY.US - Companhia Brasileira De Distribuicao](https://longbridge.com/en/quote/CBDBY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 宜瑞安｜10-K：2025 财年营收 72.19 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276171037.md) | | 阿彻丹尼尔斯米德兰｜10-K：2025 财年营收 803 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276167327.md) | | 路易斯安那太平洋｜10-K：2025 财年营收 27.08 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276152518.md) | | 我花了 90 美元进入 JFK Capital One Lounge。是否值得花 395 美元每年办一张信用卡以获得无限次进入的资格？ | 一位旅行者为进入 JFK 的 Capital One Lounge 支付了 90 美元，并考虑是否申请 Capital One Venture X 信用卡，该卡每年收费 395 美元，提供无限次的休息室访问。该卡的优惠包括在前三个月消费 4 | [Link](https://longbridge.com/en/news/276447079.md) | | 对于杰克丹尼尔的粉丝来说，肯塔基波本威士忌是一个自然的升级选择 | 杰克丹尼尔（Jack Daniel's）是一款受欢迎的威士忌，但对于那些想尝试新口味的人来说，梅克尔马克 46（Maker's Mark 46）是一个很好的替代选择。它具有更高的酒精度和独特的陈酿工艺，提供了复杂的风味特征，包括焦糖、烘焙香 | [Link](https://longbridge.com/en/news/276087148.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.